|
|
 |
|
Viewing report
|
|
|
|
Global Generics Guide 2nd Edition: Optimizing Geographical and Strategic Positioning in an Evolving Generics Landscape
Datamonitor, Nov 2003, Pages: 366
Introduction
The global generics market is changing. A favorable environment in the US has lead to intense competition in commodity generics, and left players seeking alternative options to drive further growth. Meanwhile, regulatory reform in under penetrated EU generics markets is boosting generic usage, attracting attention from overseas players, and bringing with it its own set of challenges.
Scope
Benchmarking of leading generics players by 2002 sales, market share and financial position and by forecast ethical sales between 2003 and 2008
Analysis of portfolio management and geographic expansion strategies specific to US and EU based players
Full profiles of 11 leading generics players - Alpharma, Andrx, Barr, Biovail, IVAX, Mylan, Ranbaxy, SICOR, Stada, Teva, Watson
Report Highlights
The global generics market is forecast strong growth between 2003 and 2008. In the US, patent expiries will be the key driver, with $84 billion worth of 2002 blockbusters being at risk of generic competition by 2008. Europe is expected to outperform the US in terms of rate of growth in generics sales, with increased generic usage the key driver.
Despite the introduction of cost containment measures resulting in price cuts in mature generics markets such as the UK and Germany, the net benefit of regulatory reform and cost containment measures will be positive for the European generics industry, particularly in those markets where generic penetration is currently very low.
In 2008, the best positioned generics companies will be those that have technology platforms enabling them to maintain margins in face of increased competition, and that have international manufacturing and distribution networks that allow them to profit from the growth potential in southern European markets.
Reasons to Purchase
Understand the drivers of growth in the major generics markets, and tailor your portfolio management strategy to maximize profit return
Benchmark your strategy against key rivals in the generics sector
Assess the impact of regulatory reform and increased generic penetration on the branded sector
Customers who bought this item also bought
Global Generics Guide: Capitalizing On an $82 Billion Opportunity
Global Generics Guide 3rd Edition: Benchmarking Generics Company Capabilities and Strategy
Generics: Global Industry Guide
Impact of Generics on the Antidepressant Market
The Pharmaceutical Market Outlook to 2015: Implementing innovative, long-term strategies for sustainable future growth
Generics in Europe - Premium
Global Generics
An Exploration of Consolidation in the Generics Industry
|
|
|
|
